HealthShares Launches 9 New ETF’s
This morning HealthShares(TM) ETF’s, from XShares Advisors LLC, is launching 9 new ETF’s dedicated to various aspects of healthcare. This is in addtion to the 5 launched in January, so there are now 14…
This morning HealthShares(TM) ETF’s, from XShares Advisors LLC, is launching 9 new ETF’s dedicated to various aspects of healthcare. This is in addtion to the 5 launched in January, so there are now 14…
by H.S. AyoubBioHealth Investor.com There have been many debates over the last couple of years as to the varying degree of blood clotting events associated with the use of drug-eluted cardiac stents. In the…
From Biohealth Investor Biotechnology LA JOLLA PHARMA +43.10% AURIGA LABORATORIES +19.05% BIONOVO INC +15.76% VION PHARM INC +12.58% RENOVIS INC +8.07% Diagnostic Substances NYMOX PHARM CORP +14.45% GENE LOGIC INC +6.97% REMOTEMDX INC +5.75%…
From BioHealth Investor The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative Strength by Investor’s Business Daily (3/10/07) scores out of 100 (last week’s rank, change…
From BioHealth Investor Biotechnology LA JOLLA PHARMA +30.70% NOVAVAX INC +12.64% IMMUNE RESPONSE CORP +11.86% VERNALIS PLC ADR +9.13% MEDIVATION INC +8.42% Diagnostic Substances RG GLBL LIFESTYLS +8.53% OSTEOLOGIX INC +7.55% IMMUCOR INC +5.63%…
Problems with drug-coated stents have been blamed for blood vessel blockages and clotting. Several studies showing potential dangers from implanting the devices have dropped the number of stents sold and caused a partial resurrection…
From BioHealth Investor Biotechnology TERCICA INC +20.49% CERUS CORP +18.04% LPATH INC +15.38% AURIGA LABORATORIES +11.20% EMERGENT BIOSOLUTION +8.54% Diagnostic Substances PRESSURE BIOSCIENC +10.68% ICAGEN, INC. +9.44% ORCHID CELLMARK INC +5.33% AVIGEN INC +3.72%…
by H.S. AyoubBioHealth Investor.com Bruker BioSciences (BRKR) seems primed for a great performance in 2007. The maker of mass spectrometry and x-ray detection systems for both the life science and security industries continues its…
From World Beta In her 2001 book "From Alchemy to IPO" Cynthia Robbins Roth cites a Hambrecht & Quist study of biotech stock movement surrounding clinical trial results (Phases I-III) and FDA approvals. The…
From BioHealth Investor Biotechnology ANTIGENICS INC +11.46% CADENCE PHARM. INC. +10.04% COMBINATORX +9.53% GENITOPE CORPORATION +9.24% PROGEN INDS LTD +8.84% Diagnostic Substances ICAGEN, INC. +11.11% LEXICON GENETICS I +8.44% ISTA PHARMACTLS +6.97% SYNTA PHARMACEUTICAL…
CV Therapeutics (CVTX) just showed Ranexa study for chronic chest pain (angina) that aren’t what investors were hoping for. The Phase III clinical trial studying the drug for other uses as a treatment of…
UnitedHealth (UNH-NYSE) has finally become current in its SEC Filings as of this morning, but this shouldn’t be that big of a surprise. The company did go back and restate earnings over stock option…
From BioHealth Investor Biotechnology CYPRESS BIOSCIENCE +5.81% SGX PHARMACEUTICALS +5.44% AFFYMAX, INC. +5.35% CERAGENIX PHARMACUTL +5.26% LEV PHARMACEUTICALS +5.26% Diagnostic Substances RG GLBL LIFESTYLS +10.37% COLEY PHARMACEUTICAL +6.18% MYRIAD GENETICS +4.48% REMOTEMDX INC +2.36%…
Early this morning, Memory Pharmaceuticals (MEMY) dropped a bomb with its announcement that Phase IIa results for MEM1003 failed to achieve its effectiveness targets for treatment in acute mania in bipolar disorder. It said…
From BioHealth Investors Biotechnology INSMED INC +13.87% BIODELIVERY SCI INTL +8.86% FAVRILLE, INC. +5.81% VERNALIS PLC ADR +5.51% SGX PHARMACEUTICALS +5.05% Diagnostic Substances RG GLBL LIFESTYLS +20.54% GENE LOGIC INC +10.34% HEALTHCARE TECH LTD…